# US 2001/0025040 A1 · Antihistamine leukotriene combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025040 A1
- Document ID: US20010025040A1
- Status: Published application
- Kind: A1
- Application number: 09/784,640
- Filed: 2001-02-15
- Published: 2001-09-27
- Earliest claimed: 2000-02-17
- Assignees: Asta Medica Aktiengesellschaft
- Inventors: Hildegard Poppe; Jurgen Engel; Istvan Szelenyi
- Web page: https://patentgrep.com/patent/US20010025040A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 27/02: Ophthalmic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a pharmaceutical composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis, which comprises (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, and (c) one or more of a conventional pharmaceutical vehicle, extender, and excipient, and to its use for manufacturing a composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis.

## Claims

### Claim 1

A pharmaceutical composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis, which comprises (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof (b) a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, and (c) one or more of a conventional pharmaceutical vehicle, extender, and excipient..

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, in which the nonsedating antihistamine is azelastine, levocabastine, cetirizine, fexofenadine, mizolastine, or astemizole..

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the leukotriene D4 antagonist is montelukast, zafirlukast or pranlukast.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the 5-lipoxygenase inhibitor is zileuton, piriprost or AWD 23-115.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the FLAP antagonist is MK-591, MK-886 or Bay X 1005.

### Claim 6 (depends on 1)

The pharmaceutical composition of claims 1, wherein the concentration of the nonsedating antihistamine or salt is from 0.001 wt. % to 0.5 wt. % based on the composition..

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of the leukotriene D4antagonist or salt is from 0.01 wt. % to 5 wt. % based on the composition..

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of the 5-lipoxygenase inhibitor or salt is from 0.01 wt. % to 5 wt. % based on the composition..

### Claim 9 (depends on 1)

The pharrmaceutical composition of claim 1, wherein the concentration of the FLAP antagonist or salt is from 0.01 wt. % to 5 wt. % based on the composition.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of said leukotriene D4 antagonist, 5-lipoxygenase inhibitor, or FLAP antagonist, or a pharmaceutically acce ptable salt is from 0.01 wt. % to 5 wt. % based on the composition..

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 in a dosage form for topical administration.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10 in a dosage form for oral administration.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the dosage form for topical administration is a spray.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the dosage form for topical administration is a nasal or eye drop.

### Claim 15 (depends on 1)

A process for preparing the pharmaceutical composition of claim 1, which comprises combining said antihistamine and said component (b) with said component (c) and converting the resulting combination into a dosage form for administration.

### Claim 16

Use of a composition of (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, for preparing a pharmaceutical composition or pharmaceutical agents, for the simultaneous or sequential treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis.

### Claim 17 (depends on 16)

Use of the pharmaceutical composition or ingredients of claim 16, wherein the nonsedating antihistamine is azelastine, levocabastine, cetirizine, fexofenadine, mizolastine, or astemizole.

### Claim 18 (depends on 16)

Use of the pharmaceutical composdition or ingredients of claim 16, wherein the leukotriene D4 antagonist is zafirlukast, montelukast or pranlukast, the 5-lipoxygenase inhibitor is zileuton, piripost or AWD 23-115, and the FLAP antagonist is MK-591, MK-886 or Bay 1005.

### Claim 19 (depends on 1)

A pharmaceutical package containing the pharmaceutical composition of claim 1, further containing instructions for its use for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjuntivitis.
